Literature DB >> 22262476

Metabolic pathway alterations that support cell proliferation.

M G Vander Heiden1, S Y Lunt, T L Dayton, B P Fiske, W J Israelsen, K R Mattaini, N I Vokes, G Stephanopoulos, L C Cantley, C M Metallo, J W Locasale.   

Abstract

Proliferating cells adapt metabolism to support the conversion of available nutrients into biomass. How cell metabolism is regulated to balance the production of ATP, metabolite building blocks, and reducing equivalents remains uncertain. Proliferative metabolism often involves an increased rate of glycolysis. A key regulated step in glycolysis is catalyzed by pyruvate kinase to convert phosphoenolpyruvate (PEP) to pyruvate. Surprisingly, there is strong selection for expression of the less active M2 isoform of pyruvate kinase (PKM2) in tumors and other proliferative tissues. Cell growth signals further decrease PKM2 activity, and cells with less active PKM2 use another pathway with separate regulatory properties to convert PEP to pyruvate. One consequence of using this alternative pathway is an accumulation of 3-phosphoglycerate (3PG) that leads to the diversion of 3PG into the serine biosynthesis pathway. In fact, in some cancers a substantial portion of the total glucose flux is directed toward serine synthesis, and genetic evidence suggests that glucose flux into this pathway can promote cell transformation. Environmental conditions can also influence the pathways that cells use to generate biomass with the source of carbon for lipid synthesis changing based on oxygen availability. Together, these findings argue that distinct metabolic phenotypes exist among proliferating cells, and both genetic and environmental factors influence how metabolism is regulated to support cell growth.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22262476     DOI: 10.1101/sqb.2012.76.010900

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  128 in total

Review 1.  Review of metabolic pathways activated in cancer cells as determined through isotopic labeling and network analysis.

Authors:  Wentao Dong; Mark A Keibler; Gregory Stephanopoulos
Journal:  Metab Eng       Date:  2017-02-10       Impact factor: 9.783

2.  SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.

Authors:  Davide Martino Coda; Marcello Francesco Lingua; Deborah Morena; Valentina Foglizzo; Francesca Bersani; Ugo Ala; Carola Ponzetto; Riccardo Taulli
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein.

Authors:  Jurre J Kamphorst; Michel Nofal; Cosimo Commisso; Sean R Hackett; Wenyun Lu; Elda Grabocka; Matthew G Vander Heiden; George Miller; Jeffrey A Drebin; Dafna Bar-Sagi; Craig B Thompson; Joshua D Rabinowitz
Journal:  Cancer Res       Date:  2015-02-01       Impact factor: 12.701

4.  Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer.

Authors:  John T Cunningham; Melissa V Moreno; Alessia Lodi; Sabrina M Ronen; Davide Ruggero
Journal:  Cell       Date:  2014-05-22       Impact factor: 41.582

5.  Prediction of therapeutic microRNA based on the human metabolic network.

Authors:  Ming Wu; Christina Chan
Journal:  Bioinformatics       Date:  2014-01-07       Impact factor: 6.937

6.  Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α.

Authors:  Wei Zhao; Cunjie Chang; Yangyan Cui; Xiaozhi Zhao; Jun Yang; Lan Shen; Ji Zhou; Zhibo Hou; Zhen Zhang; Changxiao Ye; Donald Hasenmayer; Robert Perkins; Xiaojing Huang; Xin Yao; Like Yu; Ruimin Huang; Dianzheng Zhang; Hongqian Guo; Jun Yan
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

Review 7.  Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming.

Authors:  Lidia de Bari; Anna Atlante
Journal:  Cell Mol Life Sci       Date:  2018-05-04       Impact factor: 9.261

8.  Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Authors:  Andrea E Calvert; Alexandra Chalastanis; Yongfei Wu; Lisa A Hurley; Fotini M Kouri; Yingtao Bi; Maureen Kachman; Jasmine L May; Elizabeth Bartom; Youjia Hua; Rama K Mishra; Gary E Schiltz; Oleksii Dubrovskyi; Andrew P Mazar; Marcus E Peter; Hongwu Zheng; C David James; Charles F Burant; Navdeep S Chandel; Ramana V Davuluri; Craig Horbinski; Alexander H Stegh
Journal:  Cell Rep       Date:  2017-05-30       Impact factor: 9.423

Review 9.  Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression.

Authors:  Zhaoyong Li; Huafeng Zhang
Journal:  Cell Mol Life Sci       Date:  2015-10-23       Impact factor: 9.261

10.  Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

Authors:  Na Xie; Zheng Tan; Sami Banerjee; Huachun Cui; Jing Ge; Rui-Ming Liu; Karen Bernard; Victor J Thannickal; Gang Liu
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.